Asset Details
Do you wish to reserve the book?
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Do you wish to request the book?
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
2010
Overview
The authors report on the clinical activity of a new oral inhibitor of Janus kinase 2 (JAK2) in patients with myelofibrosis. The drug improved a wide range of symptoms promptly, controlled them for >1 year, and appeared to inhibit disease progression to acute leukemia.
Myelofibrosis is manifested as primary myelofibrosis, post–essential thrombocythemia myelofibrosis, or post–polycythemia vera myelofibrosis and is characterized by clinical signs (e.g., progressive anemia, bone marrow fibrosis, and splenomegaly) and a constellation of debilitating symptoms (fatigue, weakness, bone pain, a hypercatabolic state, and weight loss).
1
Survival in myelofibrosis is related to the number of risk factors and ranges from 2 to 4 years among patients with two or more risk factors (intermediate-2 or high risk) to 8 to 11 years among patients with no risk factors or one risk factor (intermediate-1 or low risk) (see Table 1A in the Supplementary Appendix, available with . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Biological and medical sciences
/ Disease
/ Dose-Response Relationship, Drug
/ Female
/ Hematologic and hematopoietic diseases
/ Humans
/ Janus Kinase 1 - antagonists & inhibitors
/ Janus Kinase 2 - antagonists & inhibitors
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Male
/ Mutation
/ Patients
/ Primary Myelofibrosis - blood
/ Primary Myelofibrosis - complications
/ Primary Myelofibrosis - drug therapy
/ Primary Myelofibrosis - genetics
/ Pyrazoles - administration & dosage
/ STAT3 Transcription Factor - drug effects
/ STAT3 Transcription Factor - metabolism
/ Tumors
